Skip to main content
micro-community-banner
 
  • Saved

made a Post

Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France - PubMed

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36705644/



Conclusions: Ide-cel was associated with significant survival improvements in terms of both LYs and QALYs in patients with progressive triple-class-exposed RRMM. The ICER for ide-cel was similar to that of other approved and reimbursed RRMM therapies.

  • Saved

made a Post

Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma - International Journal of Hematology

Background In the phase 2 KarMMa trial, patients with relapsed/refractory multiple myeloma (RRMM) achieved deep and durable responses with idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) ..... see more

Source : https://link.springer.com/article/10.1007/s12185-023-03538-6


Conclusions: Ide-cel yielded deep, durable responses with a tolerable and predictable safety profile in Japanese patients with RRMM. These results are similar to those of the non-Japanese population in KarMMa.


  • Saved

made a Post

Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma - PubMed

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36651055/


Conclusions: These findings hinge on the assumption of longer-term survival but suggest that the use of CAR-T therapy is approaching standard ICER thresholds.


"

  • Saved

made a Post

Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments - PubMed

In recent years, new treatments have been studied for relapsed-refractory multiple myeloma (RRMM), including two CAR-T products and a variety of non-CAR-T agents. Since direct comparisons between these innovative treatments ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36648884/


Conclusions: While the Shiny method has confirmed its validity in reconstructing individual patient data, our indirect comparisons have offered some original clues to interpret the results of OS published in these studies.


  • Saved

made a Post

How I treat diffuse large B-cell lymphoma - PubMed

Diffuse large B-cell lymphoma (DLBCL) is usually treated with chemoimmunotherapy in curative intention at initial diagnosis. Novel agents have improved the prognosis of high-risk patients in the front-line and relapsed ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36634531/


Conclusions: Several novel drugs have improved first-line and second-line treatment of DLBCL in clinical practice. De-escalation of low-risk patients reduces acute and late side-effects. New treatment concepts such as CAR-T cells and bispecific antibodies will further improve the outcome of high-risk patients.


  • Saved

made a Post

Extreme body mass index and survival in newly diagnosed multiple myeloma patients - Blood Cancer Journal

Correspondence Open Access Published: Urvi A. Shah orcid.org/0000-0001-8419-1091 1,2 , David J. Lee 5,6 , Sabrin Tahri 6,7 , Even H. Rustad 9,10 , Sham Mailankody orcid.org/0000-0002-2815-9561 1,2 , Alexander ..... see more

Source : https://www.nature.com/articles/s41408-022-00782-7


Conclusions: This comprehensive examination of BMI and survival in newly diagnosed MM patients suggests that underweight and severe obesity are associated with worse survival. Future studies of weight trajectories and body composition may help clarify these observations. Additionally, clinical research to understand if patients with extreme BMI...

  • Saved

made a Post

Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice - PubMed

Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a cure remains elusive for ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36627265/


Conclusions: In this comprehensive review, the authors describe the development of CAR T-cell therapies in myeloma, the outcomes of notable clinical trials, the toxicities and limitations of CAR T-cell therapies, and the strategies to overcome therapeutic challenges of CAR T cells in the hope of achieving a cure for multiple myeloma.

Albert Dekker, Ali Mirmiran Commented on a Post
  • Saved
Cell-based gene therapy in multiple myeloma

The CAR T-cell field in MM has made several strides since the first BCMA-targeted CAR was developed nearly 10 years ago. Results from the pivotal phase 2 KarMMa study of idecabtagene vicleucel (ide-cel) shows promise with rapid, deep, and durable responses in patients with triple-class-exposed relapsed and refractory myeloma.

The ORR at primary analysis was 72% at a median follow-up of 13.2 months. Furthermore, 55% of patients experienced a very good partial response (VGPR) or better, with 93% of evaluable patients being MRD negative.

Ide-cel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy. It is indicated in adult patients with R/R multiple myeloma following 4+ prior lines of therapy. These prior lines of therapy include an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Ide-cel was approved by the FDA in March 2021, and each dose is a customized treatment developed based on the patient’s own T-cells. These T-cells are collected and genetically modified to incorporate a new gene that targets and kills myeloma cells. Modified cells are infused into the patient.

What have your experiences with ide-cel been compared with other BRMA-targeted CAR T cell therapy? In your opinion/experience, will ide-cel have a prominent place in R/R multiple myeloma?

Show More Comments

  • January 14, 2023
    I think with BITEs there will be more room for CAR-T patients at academic centers
  • January 14, 2023
    I have had personal experience using ABECMA in my patients. I had seen good responses and reasonably good tolerability in my patients.
  • Saved

made a Post

Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US - Clinical Drug Investigation

Background Gene therapy is known to be unaffordable to those who need it the most; however, evidence on the financial impact is limited. Objective This study aimed to estimate the ..... see more

Source : https://link.springer.com/article/10.1007/s40261-022-01215-w


Conclusions: This study suggests that the high cost of the gene therapy idecabtagene vicleucel is justifiable due to the low number of rrMM patients.


  • Saved

made a Post

phase II clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma

Brief Report | Nicola Giesen, Manik Chatterjee, Christof Scheid, Alexandra M Poos, Britta Besemer, Kaya Miah, Axel Benner, Nicole Becker, Thomas Moehler, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, ..... see more

Source : https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2022017789/494022/A-phase-II-clinical-trial-of-combined-BRAF-MEK?redirectedFrom=fulltext


Conclusions: This is the first prospective clinical trial to demonstrate that combined BRAF/MEK inhibition is highly effective in patients with BRAFV600E mutated RRMM and represents a successful targeted precision medicine approach in this disease.


  • Saved

made a Post

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors

Chimeric antigen receptor T (CAR-T) cells technology has been successfully used in the treatment of B cell-derived hematological tumors and multiple myeloma. CAR-T cells are also being studied in a ..... see more

Source : https://www.frontiersin.org/articles/10.3389/fimmu.2022.1079181/full



Conclusions: In this review, we summarized the serious adverse events of CAR-T cells in the treatment of malignant tumors by reading literature and searching relevant clinical studies, and discussed the management and treatment of serious adverse events in an effort to provide theoretical support for clinicians who deal with such patients.

  • Saved

made a Post

The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers | CEOR

Multiple myeloma (MM) is a malignant clonal plasma cell proliferative disorder characterized by uncontrolled and progressive increase of monoclonal paraprotein leading to specific end-organ damage. The proliferating multiple myeloma cells ..... see more

Source : https://www.dovepress.com/the-burden-of-a-multiple-myeloma-diagnosis-on-patients-and-caregivers--peer-reviewed-fulltext-article-CEOR


Conclusions: NDMM is burdensome for patients and caregivers in the first year after diagnosis. TNE patients are more dependent on caregivers and incur higher care costs than TE patients. Despite the financial, physical, and emotional burden, HRQoL remains stable possibly indicating resilience and illness adjustment amongst patients and...

  • Saved

made a Post

Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma - PubMed

Data collected to date support CAR-T therapies holding substantial promise for patients with heavily pretreated RRMM relative to other currently available therapies. Additional real-world data will help provide further insights ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36411210/


Conclusions: Data collected to date support CAR-T therapies holding substantial promise for patients with heavily pretreated RRMM relative to other currently available therapies. Additional real-world data will help provide further insights into the comparative efficacy and safety profiles of these treatments in RRMM as these treatments become...

  • Saved

made a Post

Innovation in BCMA CAR-T therapy: Building beyond the Model T - PubMed

Autologous chimeric antigen receptor T-cell (CAR-T) therapies targeting B-cell maturation antigen (BCMA) have revolutionized the field of multiple myeloma in the same way that the Ford Model T revolutionized the ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36505779/


Conclusions: Conclusions/Relevance: Just as the Model T set a benchmark for car manufacturing over 100 years ago, idecabtagene vicleucel and ciltacabtagene autoleucel have now set the starting point for BCMA CAR-T therapy with their approvals. As with any emerging technology, whether automotive or cellular, the best in innovation and...

  • Saved

made a Post

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma - PubMed

Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35332278/


Relevance: Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion is the first prospective study of real-life standard of care (SOC) in triple-class exposed...

  • Saved

made a Post

New and emerging pharmacotherapies for management of multiple myeloma

You do not currently have access to this article. Subscription prices and ordering for this journal Don't already have an Oxford Academic account? Register New and emerging pharmacotherapies for management ..... see more

Source : https://academic.oup.com/ajhp/advance-article-abstract/doi/10.1093/ajhp/zxac091/6554284?redirectedFrom=fulltext&login=false


Conclusion: Several therapeutic agents have been recently approved by the Food and Drug Administration for the treatment of multiple myeloma. There are many novel agents in the pipeline, including bispecific antibodies and CAR T-cell therapies that have the potential to continue to change the treatment landscape of multiple myeloma.

  • Saved

made a Post

Highly expressed genes in multiple myeloma cells - what can they tell us about the disease? - PubMed

Cancer cells can convert proto-oncoproteins into oncoproteins by increasing the expression of genes that are oncogenic when expressed at high levels. Such genes can promote oncogenesis without being mutated. To ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35276027/


Conclusion/Relevance: Many well-known "myeloma genes" such as MCL1, CXCR4, TNFRSF17, SDC1, SLAMF7, PTP4A3, and XBP1 were identified as highly expressed, and we believe that hitherto unrecognized key players in myeloma pathogenesis are also enriched on the list. Highly expressed genes in malignant plasma cells that were absent or expressed at...

  • Saved

made a Post

Exosomal miR-483-5p in Bone Marrow Mesenchymal Stem Cells Promotes Malignant Progression of Multiple Myeloma by Targeting TIMP2

Bone marrow-derived mesenchymal stem cell (BMSC) is one crucial component of the multiple myeloma (MM) microenvironment and supports the malignant progression of MM. Whether BMSCs act on MM cells via ..... see more

Source : https://www.frontiersin.org/articles/10.3389/fcell.2022.862524/full


Conclusion/Relevance: In summary, our study indicated that MM-MSCs promote MM malignant progression via the release of exosomes and regulation of miR-483-5p/TIMP2 axis, suggesting an essential role of BMSCs derived exosomal miRNA in MM and a potential marker for MM diagnosis and therapy.

  • Saved

made a Post

Exosomes in Multiple Myeloma: from bench to bedside

Multiple myeloma (MM) remains till today an incurable plasma cell malignancy which develops in the bone marrow (BM). This BM is partially responsible for protec see more

Source : https://ashpublications.org/blood/article/doi/10.1182/blood.2021014749/484361/Exosomes-in-Multiple-Myeloma-from-bench-to-bedside


Conclusion/Relevance: In this review we will summarize the current findings of exosome-related processes in the BM and describe not only the current treatment strategies to counter them but also how exosomes can be harnessed to deliver toxic payloads. Finally, an overview of the different clinical studies which investigate EV cargo as...

  • Saved

made a Post

Role of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms

The IL-1 receptor antagonist (IL-1Ra or IL-1RN) functions as a competitive antagonist of the cell surface IL-1 receptor. * IL-4 is a potent anti-inflammatory cytokine. * It was aimed to ..... see more

Source : https://www.sciencedirect.com/science/article/abs/pii/S1043466622000606?via=ihub


Conclusions: In conclusion, with this study, the effects of IL-1RN VNTR and IL-4 VNTR polymorphisms on MM were evaluated for the first time in the literature. This study will shed light on ones on cytokine-MM relationship and epigenetic mechanisms.